Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
LEXICON PHARMACEUTICALS, INC. director Philippe Amouyal received new equity awards as part of his compensation. On May 1, 2026, he was granted 43,478 stock options to buy common stock at an exercise price of $1.61 per share, expiring on May 1, 2036.
The option vests in three equal annual installments over the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units (RSUs), which vest in full on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock, with no open-market buying or selling reported in this filing.
LEXICON PHARMACEUTICALS director Christopher J. Sobecki received new equity awards as part of his compensation. On May 1, 2026, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date, with each unit representing a contingent right to receive one share of common stock. These are awards from the company rather than open‑market purchases or sales.
LEXICON PHARMACEUTICALS director Sam L. Barker received new equity awards. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date.
He also received 35,714 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the first anniversary of the grant date, providing additional equity-based compensation tied to continued service.
Lexicon Pharmaceuticals director Ivan Cheung received new equity awards as part of his compensation. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. This option vests in three equal annual installments over the first three anniversaries of the grant date.
He was also granted 35,714 restricted stock units, each representing a contingent right to receive one share of common stock. These RSUs vest in full on the first anniversary of the grant date. Both awards are reported as directly owned and represent routine, compensation-related acquisitions rather than open-market purchases or sales.
LEXICON PHARMACEUTICALS director Judith L. Swain received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date and expiring on May 1, 2036. She was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.
LEXICON PHARMACEUTICALS director Diane E. Sullivan received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options covering 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. The option vests in three equal annual installments on each of the first three anniversaries of the grant date.
She was also granted 35,714 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the first anniversary of the grant date. These are non-cash, compensation-related grants, with no open-market purchases or sales reported in this filing.
Lexicon Pharmaceuticals director Raymond Debbane received new equity awards. On May 1, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring in 2036.
The option vests in three equal annual installments on each of the first three anniversaries of the grant date. He also received 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.
Lexicon Pharmaceuticals, Inc. converted its Series B Convertible Preferred Stock into common shares and expanded its equity plans and authorized share capital. On April 30, 2026, all 408,434.7 outstanding Series B preferred shares were automatically converted into 20,421,735 shares of common stock at a 50-to-1 ratio under the existing terms, relying on a Section 3(a)(9) exemption.
Stockholders approved a 2026 Equity Incentive Plan, increasing the common stock available for awards from 75,000,000 to 90,000,000 shares, and a 2026 Non-Employee Directors’ Equity Incentive Plan, increasing its pool from 4,000,000 to 6,000,000 shares. Both plans now run through February 12, 2036. Lexicon also filed a Seventh Amended and Restated Certificate of Incorporation, effective on filing, raising authorized common stock from 450,000,000 to 900,000,000 shares, with related charter and equity plan items and auditor ratification approved at the annual meeting.
Lexicon Pharmaceuticals filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company reported an aggregate market value of voting stock held by non-affiliates of $170.0 million based on a $0.95 closing price as of June 30, 2025, and stated 423,680,611 shares outstanding as of March 4, 2026.
The company is focused on advancing sotagliflozin (commercialized as INPEFA and pursued as ZYNQUISTA), pilavapadin (LX9211), and LX9851. FDA proceedings for ZYNQUISTA include two complete response letters and an ongoing public Notice of Opportunity for Hearing; the company may resubmit its NDA contingent on third-party study data. Lexicon disclosed collaboration agreements with Novo Nordisk, Viatris and Bristol-Myers Squibb and reported $61.1 million in R&D expenses for 2025.
Lexicon Pharmaceuticals is asking stockholders to vote at its April 30, 2026 annual meeting on several key items. The company proposes doubling authorized common shares from 450,000,000 to 900,000,000, which would leave 376,875,534 shares authorized but not issued or reserved after assumed conversions and plan approvals. Stockholders are also asked to approve a new 2026 Equity Incentive Plan increasing the share pool to 90,000,000 and a 2026 Non-Employee Directors’ Equity Incentive Plan with up to 6,000,000 shares. Other proposals include electing three Class II directors, an advisory vote on executive compensation, and ratifying Ernst & Young LLP as independent auditors for the year ending December 31, 2026. Common stockholders of record on March 6, 2026, when 423,680,611 shares were outstanding, are entitled to one vote per share.